INFO & CONTACTS:  +39 02 2390 1

CARE1: A first-line, randomized platform study to optimize treatment in patients with metastatic renal cell carcinoma.

Phase: Phase II-III clinical trials

Principal Investigator: Dott. Procopio Giuseppe

Main Facility: Oncologia Medica Genitourinaria

Drug: all drugs in clinical practice group A (dual immunotherapy NIVO + IPI Q4W) group B (immunotherapy + anti-angiogenic)

Pathologies: Urological cancers (kidney, bladder, urinary tract, others)

An international, multicenter, open-label, randomized, controlled Phase 3 study comparing the ICI-ICI combination with nivolumab-ipilimumab versus the VEGFR-TKI-ICI combination (axitinib-pembrolizumab, nivolumab-cabozantinib, or lenvatinib-pembrolizumab, at the investigator's discretion based on the available agent). Patients will be stratified by PDL1 status, defined by PDL1 immunohistochemistry (considered positive when >1% of tumor cells are identified by the local pathologist).

Last update: 20/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe